583. <i>SARS-CoV-2</i> Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian Physicians
Abstract Background Peru started its national vaccination campaign in February 2021 using Sinopharm vaccine, targeting healthcare personnel on its initial phase. Although the immunogenicity of this vaccine was tested in clinical trials, there are no studies that evaluated the humoral response post v...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2021
|
| Materias: | |
| Acceso en línea: | Descargar el archivo Enlace permanente (DOI o Handle) Enlace permanente (DOI o Handle) |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1881508873063366656 |
|---|---|
| author | María Victoria Lopera Romina Vera Carlos Tapia Carlos Cabrera Jose Armando Gonzales Zamora Jorge Alave |
| author_browse | Carlos Cabrera Carlos Tapia Jorge Alave Jose Armando Gonzales Zamora María Victoria Lopera Romina Vera |
| author_facet | María Victoria Lopera Romina Vera Carlos Tapia Carlos Cabrera Jose Armando Gonzales Zamora Jorge Alave |
| author_sort | María Victoria Lopera |
| collection | Producción científica |
| description | Abstract Background Peru started its national vaccination campaign in February 2021 using Sinopharm vaccine, targeting healthcare personnel on its initial phase. Although the immunogenicity of this vaccine was tested in clinical trials, there are no studies that evaluated the humoral response post vaccination in Peru. Methods We conducted a cross sectional study, which objective was to evaluate the humoral immunogenicity triggered by the Sinopharm vaccine in Peruvian physicians. We collected demographic and epidemiologic data via an electronic. The SARS-CoV-2 spike protein S1/S2 antibodies were measured by chemiluminescense (Liaison®). A positive test was defined as >15 U/ml, which has correlation of 95% with neutralizing antibodies measured by plaque reduction neutralizing test. Results 92 participants were enrolled in the study. The epidemiologic characteristics are described in table 1. The mean level of antibodies measured at least 2 weeks from the second vaccine dose was 67.5 ± 70.5 U/ml. 85.7% of the study cohort had positive S1/S2 antibodies. In the univariate analysis, an imperfect negative correlation was found between the level of antibodies and participants’ age (r= -0.24; regression F test 5.25; p = 0.0242). A weak negative correlation was observed between the antibody titer and the time elapsed from the second vaccine dose and the day of antibody measurement (r= -0.17). A higher antibody level post vaccine was found in individuals who worked in COVID units (105.5 U / mL vs 58.2 U / mL; p = 0.0125), and in participants with history of COVID (216.5 U / mL vs 81.2 U / mL; p = < 0.0000). Hypertension was associated with lower antibody titers (36.9 U / mL vs. 74.6; p = 0.0464). In the multivariate analysis, working in COVID units, having previous COVID infection and shorter time from second vaccine dose and day of antibody measurement were associated with higher antibody levels post vaccine (table 2). Conclusion Our study showed that the time elapsed from the second vaccine dose and the day of antibody measurement, having previous COVID-19 infection and working in COVID -19 units may help to predict higher antibody titers post vaccine. Larger studies to evaluate the humoral response post Sinopharm vaccine and its clinical implications are still needed in Peru. Disclosures All Authors: No reported disclosures |
| format | Article |
| id | oai:cris.upeu.edu.pe:20.500.15037/176 |
| institution | UPeU |
| language | English |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| record_format | dspace |
| spelling | oai:cris.upeu.edu.pe:20.500.15037/1762026-10-30T16:14:32Z583. <i>SARS-CoV-2</i> Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian PhysiciansMaría Victoria LoperaRomina VeraCarlos TapiaCarlos CabreraJose Armando Gonzales ZamoraJorge AlaveMedicineImmunogenicityVaccinationAntibodyTiterCohortNeutralizing antibodyAntibody titerImmunologyCoronavirus disease 2019 (COVID-19)Internal medicineVirologyDiseaseInfectious disease (medical specialty)MedicineImmunogenicityVaccinationAntibodyTiterCohortNeutralizing antibodyAntibody titerImmunologyCoronavirus disease 2019 (COVID-19)Internal medicineVirologyDiseaseHealth Sciences Medicine Infectious Diseases SARS-CoV-2 and COVID-19 ResearchLife Sciences Biochemistry, Genetics and Molecular Biology Molecular Biology vaccines and immunoinformatics approachesHealth Sciences Medicine Infectious Diseases COVID-19 Clinical Research StudiesAbstract Background Peru started its national vaccination campaign in February 2021 using Sinopharm vaccine, targeting healthcare personnel on its initial phase. Although the immunogenicity of this vaccine was tested in clinical trials, there are no studies that evaluated the humoral response post vaccination in Peru. Methods We conducted a cross sectional study, which objective was to evaluate the humoral immunogenicity triggered by the Sinopharm vaccine in Peruvian physicians. We collected demographic and epidemiologic data via an electronic. The SARS-CoV-2 spike protein S1/S2 antibodies were measured by chemiluminescense (Liaison®). A positive test was defined as >15 U/ml, which has correlation of 95% with neutralizing antibodies measured by plaque reduction neutralizing test. Results 92 participants were enrolled in the study. The epidemiologic characteristics are described in table 1. The mean level of antibodies measured at least 2 weeks from the second vaccine dose was 67.5 ± 70.5 U/ml. 85.7% of the study cohort had positive S1/S2 antibodies. In the univariate analysis, an imperfect negative correlation was found between the level of antibodies and participants’ age (r= -0.24; regression F test 5.25; p = 0.0242). A weak negative correlation was observed between the antibody titer and the time elapsed from the second vaccine dose and the day of antibody measurement (r= -0.17). A higher antibody level post vaccine was found in individuals who worked in COVID units (105.5 U / mL vs 58.2 U / mL; p = 0.0125), and in participants with history of COVID (216.5 U / mL vs 81.2 U / mL; p = < 0.0000). Hypertension was associated with lower antibody titers (36.9 U / mL vs. 74.6; p = 0.0464). In the multivariate analysis, working in COVID units, having previous COVID infection and shorter time from second vaccine dose and day of antibody measurement were associated with higher antibody levels post vaccine (table 2). Conclusion Our study showed that the time elapsed from the second vaccine dose and the day of antibody measurement, having previous COVID-19 infection and working in COVID -19 units may help to predict higher antibody titers post vaccine. Larger studies to evaluate the humoral response post Sinopharm vaccine and its clinical implications are still needed in Peru. Disclosures All Authors: No reported disclosuresArticlehttps://academic.oup.com/ofid/article-pdf/8/Supplement_1/S394/41527311/ofab466.781.pdfhttps://doi.org/10.1093/ofid/ofab466.78110.1093/ofid/ofab466.781https://hdl.handle.net/20.500.15037/176W4200122613enOpen Forum Infectious Diseases2328-89572021-11-012026-06-13T07:48:59Z2026-06-13T07:48:59Z |
| spellingShingle | Medicine Immunogenicity Vaccination Antibody Titer Cohort Neutralizing antibody Antibody titer Immunology Coronavirus disease 2019 (COVID-19) Internal medicine Virology Disease Infectious disease (medical specialty) Medicine Immunogenicity Vaccination Antibody Titer Cohort Neutralizing antibody Antibody titer Immunology Coronavirus disease 2019 (COVID-19) Internal medicine Virology Disease Health Sciences Medicine Infectious Diseases SARS-CoV-2 and COVID-19 Research Life Sciences Biochemistry, Genetics and Molecular Biology Molecular Biology vaccines and immunoinformatics approaches Health Sciences Medicine Infectious Diseases COVID-19 Clinical Research Studies María Victoria Lopera Romina Vera Carlos Tapia Carlos Cabrera Jose Armando Gonzales Zamora Jorge Alave 583. <i>SARS-CoV-2</i> Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian Physicians |
| title | 583. <i>SARS-CoV-2</i> Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian Physicians |
| title_full | 583. <i>SARS-CoV-2</i> Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian Physicians |
| title_fullStr | 583. <i>SARS-CoV-2</i> Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian Physicians |
| title_full_unstemmed | 583. <i>SARS-CoV-2</i> Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian Physicians |
| title_short | 583. <i>SARS-CoV-2</i> Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian Physicians |
| title_sort | 583 lt i gt sars cov 2 lt i gt spike protein s1 s2 antibodies after vaccination with sinopharm in peruvian physicians |
| topic | Medicine Immunogenicity Vaccination Antibody Titer Cohort Neutralizing antibody Antibody titer Immunology Coronavirus disease 2019 (COVID-19) Internal medicine Virology Disease Infectious disease (medical specialty) Medicine Immunogenicity Vaccination Antibody Titer Cohort Neutralizing antibody Antibody titer Immunology Coronavirus disease 2019 (COVID-19) Internal medicine Virology Disease Health Sciences Medicine Infectious Diseases SARS-CoV-2 and COVID-19 Research Life Sciences Biochemistry, Genetics and Molecular Biology Molecular Biology vaccines and immunoinformatics approaches Health Sciences Medicine Infectious Diseases COVID-19 Clinical Research Studies |
| topic_facet | Medicine Immunogenicity Vaccination Antibody Titer Cohort Neutralizing antibody Antibody titer Immunology Coronavirus disease 2019 (COVID-19) Internal medicine Virology Disease Infectious disease (medical specialty) Medicine Immunogenicity Vaccination Antibody Titer Cohort Neutralizing antibody Antibody titer Immunology Coronavirus disease 2019 (COVID-19) Internal medicine Virology Disease Health Sciences Medicine Infectious Diseases SARS-CoV-2 and COVID-19 Research Life Sciences Biochemistry, Genetics and Molecular Biology Molecular Biology vaccines and immunoinformatics approaches Health Sciences Medicine Infectious Diseases COVID-19 Clinical Research Studies |
| url | https://academic.oup.com/ofid/article-pdf/8/Supplement_1/S394/41527311/ofab466.781.pdf https://doi.org/10.1093/ofid/ofab466.781 https://hdl.handle.net/20.500.15037/176 |
| work_keys_str_mv | AT mariavictorialopera 583ltigtsarscov2ltigtspikeproteins1s2antibodiesaftervaccinationwithsinopharminperuvianphysicians AT rominavera 583ltigtsarscov2ltigtspikeproteins1s2antibodiesaftervaccinationwithsinopharminperuvianphysicians AT carlostapia 583ltigtsarscov2ltigtspikeproteins1s2antibodiesaftervaccinationwithsinopharminperuvianphysicians AT carloscabrera 583ltigtsarscov2ltigtspikeproteins1s2antibodiesaftervaccinationwithsinopharminperuvianphysicians AT josearmandogonzaleszamora 583ltigtsarscov2ltigtspikeproteins1s2antibodiesaftervaccinationwithsinopharminperuvianphysicians AT jorgealave 583ltigtsarscov2ltigtspikeproteins1s2antibodiesaftervaccinationwithsinopharminperuvianphysicians |